A&O Shearman has advised Shionogi on its hearing loss collaboration with Cilcare

Published Date
Jun 25, 2024
A&O Shearman has advised Shionogi & Co., Ltd. (Shionogi) on its global option and license arrangements with Cilcare Dev SAS (Cilcare) relating to two compounds (CIL001 and CIL003) aimed at treating cochlear synaptopathy.

Cilcare is a biotechnology company which specializes in clinical research and development in the field of neurosciences and otology, specializing in the use of modern technology to develop pharmaceuticals, medical devices, and gene and cell therapy development that aims to treat noise-induced hearing loss, synaptopathy, drug-induced ototoxicity, tinnitus and otitis. 

The transaction is structured as an option to enter into global licensing arrangements for the development, manufacture and commercialization of products containing CIL001 and CIL003. 

Tokutaka Ito (Tokyo partner) led the team advising Shionogi.

Jim Ford (London partner) and Megan McMellon (London senior associate) led the team advising on the option and licensing arrangements, supported by Millie Fantham (London associate). 

Frederic Moreau (Paris partner) provided French law advice, supported by Flora Leon-Serviere (Paris counsel) and Etienne Cavalier (Paris associate).